[Autom. eng. transl.] Osteoporosis is a highly prevalent clinical condition in our country, especially among women. Osteoporotic fractures strongly undermine the quality of life of those affected and have a strong social impact as they usually generate the loss of self-sufficiency and frequently cause mortality. The analysis of the costs deriving from this condition poses important questions given the difficulty of quantifying the burden of disease. Osteoporosis, in fact, often remains silent for years, only to manifest itself suddenly and dramatically with fractures. Precisely for this reason, most economic assessments have mostly focused on osteoporotic fractures. In the report of the International Osteoporosis Foundation of 2008 the direct hospital costs for hip fractures in Italy were directly attributable to femoral fractures amounting to € 13 million. The average annual cost for a woman with an osteoporotic fracture is € 2,241.96. In Italy, in 2009, there was a rate of hospital discharge under RO for an osteoporotic fracture of 35.60 per 100,000 women aged 45 and over. The rate increases with increasing age in both the total and for all the types of fracture considered. By consulting the data in the Osmed Report, it can be seen that the total expenditure for musculoskeletal drugs amounts to € 1,378 million. These drugs are used more and more with increasing age; in particular, in the last two years there has been a progressive increase in the use of women, probably due to the changes in Note 79 which since 2007 have led to a widening of the statute of limitations on SSN. At the territorial level, the largest proportion of the expenditure for this therapeutic group is represented precisely by the drugs for osteoporosis.
|Translated title of the contribution||[Autom. eng. transl.] Osteoporosis in Italy: resources used by the NHS and related costs|
|Number of pages||13|
|Journal||Italian Journal of Public Health|
|Publication status||Published - 2011|